文献速递前列腺癌

多西他赛化疗期间使用二甲双胍对合并糖尿病的去势抵抗性前列腺癌患者前列腺癌特异性生存和总生存的影响

The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
PubMed 文献 · J Urol · 2016-10-28

该回顾性队列研究利用加拿大安大略省多个行政医疗数据库,纳入65岁以上、诊断为转移性去势抵抗性前列腺癌并接受多西他赛治疗的男性,按糖尿病状态和降糖药使用分组,评估化疗期间使用二甲双胍对前列腺癌特异性生存和总生存的影响。结果显示,二甲双胍联合多西他赛未改善前列腺癌特异性生存(p=0.9562)或总生存(p=0.9927)。

要点

  • 二甲双胍联合多西他赛未改善前列腺癌特异性生存(p=0.9562)。
  • 二甲双胍联合多西他赛未改善总生存(p=0.9927)。
  • 二甲双胍可能不是转移性去势抵抗性前列腺癌的有效化疗增敏剂。

核心结论

  • 多西他赛化疗期间使用二甲双胍未显著改善合并糖尿病的转移性去势抵抗性前列腺癌患者的前列腺癌特异性生存或总生存。
  • 本研究提示二甲双胍可能不是转移性去势抵抗性前列腺癌的有效化疗增敏剂。

研究设计与样本

  • 回顾性队列研究,使用加拿大安大略省多个行政医疗数据库的数据。
  • 纳入65岁以上、诊断为转移性去势抵抗性前列腺癌并接受多西他赛治疗的男性,按糖尿病状态和降糖药使用情况分组。
  • 采用Kaplan-Meier生存曲线、log rank检验和多因素Cox比例风险比评估二甲双胍联合多西他赛对前列腺癌特异性生存和总生存的影响。

主要发现

  • 生存曲线显示,二甲双胍联合多西他赛未改善前列腺癌特异性生存(p=0.9562)。
  • 生存曲线显示,二甲双胍联合多西他赛未改善总生存(p=0.9927)。
  • 风险比显示,二甲双胍联合多西他赛对前列腺癌特异性生存无显著影响(HR=0.96,p=0.66)。
  • 风险比显示,二甲双胍联合多西他赛对总生存无显著影响(HR=0.94,p=0.39)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Docetaxel is the first line chemotherapy currently used to treat patients with symptomatic metastatic castration resistant prostate cancer. Although it provides survival benefits, it is associated with significant side effects. Novel therapeutic options are needed for patients with metastatic castration resistant prostate cancer and an approach is combining docetaxel with chemosensitizing agents. Metformin has been shown to improve the survival of patients with breast, lung and endometrial cancer receiving chemotherapy, and enhance chemotherapeutic efficacy in breast cancer and colon cancer cells. However, to our knowledge the chemosensitizing effect of metformin in prostate cancer has not been explored. Therefore, the hypothesis for our study was that diabetic patients with metastatic castration resistant prostate cancer who were administered metformin during docetaxel chemotherapy would have improved prostate cancer specific and overall survival. MATERIALS AND METHODS: This retrospective cohort study used data from several Ontario administrative health care databases. Men older than 65 years diagnosed with metastatic castration resistant prostate cancer and treated with docetaxel were stratified into groups based on diabetes status and use of antidiabetic medications. We evaluated the effect of metformin use with docetaxel on prostate cancer specific survival and overall survival using Kaplan-Meier survival curves, the log rank test and multivariate Cox proportional HRs. RESULTS: Survival curves showed that metformin use with docetaxel did not improve prostate cancer specific survival (p = 0.9562) or overall survival (p = 0.9927). HRs showed no significant effect of metformin use with docetaxel on prostate cancer specific survival (HR = 0.96, p = 0.66) or overall survival (HR = 0.94, p = 0.39). CONCLUSIONS: Metformin use during docetaxel chemotherapy did not significantly improve prostate cancer specific or overall survival in diabetic patients with metastatic castration resistant prostate cancer. This study indicates that metformin may not be an effective chemosensitizer for metastatic castration resistant prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mayer MJ, Klotz LH, Venkateswaran V, et al. The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. J Urol. 2016. PMID: 27984108. doi:10.1016/j.juro.2016.10.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。